Pharnext【ALPHA】銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

通貨

0.0002

買値

0.0002

売値

0.0001

出来高

0.00

0.00 日の範囲 0.00

0.0001 52 週間の範囲 1.21

時価総額

17.505

前日終値

0.0002

始値

時刻

最終取引時間

財務取引量

VWAP

平均取引量 (3 か月)

0.00

発行済株式数

87,525

配当利回り

PER

-15.90

1 株当たり利益 (EPS)

-314.39

歳入

174k

純利益

-27.52M

セクター

Pharmaceutical Preparations

業界

Pharmaceutical Preparations

ウェブサイト

pharnext.com/

本社

Suresnes, Hauts-de-seine, Fra

設立

Pharnext is listed in the Pharmaceutical Preparations sector of the ユーロネクスト with ticker ALPHA. The last closing price for Pharnext was 0.00 €. Over the last year, Pharnext shares have traded in a share price range of 0.0001 € to 1.21 €.

Pharnext currently has 87,525 shares in issue. The market capitalisation of Pharnext is 17.51 € . Pharnext has a price to earnings ratio (PE ratio) of -15.90.

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts

NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference (“dbVIC”) on Wednesday, November 8 and Thursday...

New Data from the Open-Label PLEO-CMT-FU Trial Shows Sustained Benefit with PXT3003 in Patients with Charcot-Marie-Tooth Disease Type 1A After 5 Years of Total Trial Time

New Data from the Open-Label PLEO-CMT-FU Trial Shows Sustained Benefit with PXT3003 in Patients with Charcot-Marie-Tooth Disease Type 1A After 5 Years of Total Trial Time New Data from the...

Interim Analysis from the Ongoing Open-Label Phase III Extension Study Shows Sustained Benefits of PXT3003 for Patients with ...

Interim Analysis from the Ongoing Open-Label Phase III Extension Study Shows Sustained Benefits of PXT3003 for Patients with Charcot-Marie-Tooth Disease Type 1A (‘CMT1A’) New results suggest good...

Une analyse intermédiaire de l’étude de Phase III d’extension en ouvert en cours montre un benefice durable du traiteme...

Une analyse intermédiaire de l’étude de Phase III d’extension en ouvert en cours montre un benefice durable du traitement avec PXT3003 chez les patients atteints de la maladie de...

Europäische Arzneimittelagentur stimmt dem pädiatrischen Prüfkonzept für PXT3003 von Pharnext zu

Diese Zustimmung bereitet den Weg für die Stellung eines Marktzulassungsantrags in Europa Pharnext SA (Paris:ALPHA) (FR0011191287 – ALPHA), ein biopharmazeutisches Unternehmen und...

European Medicines Agency Agrees with Pharnext’s Pediatric Investigation Plan for PXT3003

This agreement paves the way for the submission of a marketing authorization application in Europe Regulatory News: Pharnext SA (Paris:ALPHA) (FR0011191287 – ALPHA), a...

Pharnext will Topline-Ergebnisse der zulassungsrelevanten Phase-3-Studie zu PXT3003 zur Behandlung der Charcot-Marie-Tooth-Kr...

Pharnext SA (Paris:ALPHA) (FR0011191287 - ALPHA), ein biopharmazeutisches Unternehmen und Vorreiter eines neuen Ansatzes zur Entwicklung innovativer Medikamentenkombinationen, die auf Big...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0.0002	0.0002	0.0002	0	0	DE
4	0	0	0.0002	0.0002	0.0002	0	0	DE
12	0	0	0.0002	0.0002	0.0002	0	0	DE
26	-0.0576	-99.6539792388	0.0578	0.0635	0.0001	3073376	0.00168859	DE
52	-0.0083	-97.6470588235	0.0085	1.21	0.0001	28505234	0.00118255	DE
156	-0.1288	-99.8449612403	0.129	1.95	0.0001	61167185	0.00383234	DE
260	-4.3998	-99.9954545455	4.4	7	0.0001	37524342	0.00731309	DE

出来高
値上がり率
値下がり率

銘柄コード	株価	出来高
MLAAHAmatheon Agri Holding NV	0.0205 € (105.00%)	1
ALMASMastrad	0.012 € (20.00%)	3.13M
ALGAUGaussin	0.042 € (16.67%)	300.36k
ALHAFHaffner Energy SA	0.961 € (15.92%)	91.1k
ALCBXCibox Interactive	0.0364 € (15.19%)	2.16M
BIDSGascogne DS	0.002 € (-50.00%)	106.74k
MLUMGUmalis Group	1.30 € (-31.22%)	1.71k
MLNMAMiguet Et Associes	0.075 € (-24.62%)	1.72k
MLSEQSequa Petroleum NV	0.008 € (-20.00%)	23k
ALMCPMcphy Energy	1.072 € (-18.91%)	196.47k
BCPBanco Comercial Portugues SA	0.4419 € (-1.10%)	43.55M
ALNEVNeovacs	0.0002 € (0.00%)	40.36M
ALCYBCybergun	0.0001 € (0.00%)	26.32M
ALDRVDrone Volt	0.0035 € (0.00%)	5.96M
ALSRSSirius Media	0.0157 € (6.08%)	5.05M